1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Healthcare Information Services
Welsis Corp.

Welsis Corp.

WLSS
Welsis Corp.US flagOther OTC
2.49
USD
- -
- -
6.85MMarket Cap
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
0.01
- -
- -
- -
Basic EPS, GAAP
-0.02
-0.01
-0.01
-0.02
-0.02
Free Cash Flow per Basic Share
-0.03
-0.02
-0.01
-0.02
-0.02
Dividend per Share
- -
- -
- -
- -
- -
Book Value per Share
-0.04
-0.05
-0.06
-0.08
-0.09
Tangible Book Value per Share
-0.04
-0.05
-0.03
-0.05
-0.06
Basic Weighted Avg Shares
3
3
3
3
3
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
Operating Margin (%)
- -
-119.97
-2,894.9
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-132.91
-1,234.15
- -
- -
Working Capital
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3
3
3
Market Capitalization
8
10
7

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'26
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
67.7%
Free Cash Flow
- -
- -
66.61%
Net Income, GAAP
- -
- -
145.88%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.01
-0.01
- -
-0.01
2025
-0.01
- -
- -
- -
-0.02
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Boon Kit Kwok
Full Time Employees
1
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Address
701 E Cathedral Road Philadelphia PA United States of America 19128
IPO Date
May 20, 2024
CIK
0001887912
Website
welsis.com
Similar Companies
M3, Inc. (MTHRY)
Aclarion, Inc. (ACONW)
NantHealth, Inc. (NH)
Science 37 Holdings, Inc. (SNCE)
Kneat.com, Inc. (KSI.TO)
XtalPi Holdings Ltd (2228.HK)
Business
Welsis Corp. (WLSS) is a development-stage company providing online psychological help services, also known as teletherapy or telepsychology, through a platform offering counseling and psychological support for adolescents from age 14 and adults, for men and women; therapy for individuals, couples, and families; and a cryptocurrency exchange platform via TokenTraders.net that enables users to exchange and trade digital assets. The company operates in the healthcare services industry, specifically health information and medical/nursing services segments, with a primary focus on virtual therapy solutions delivered by licensed therapists. Incorporated in Wyoming on August 16, 2021, and headquartered at 701 E. Cathedral Road, Suite 45 PMB 405, Philadelphia, Pennsylvania 19128, United States, Welsis maintains a minimal operational footprint with one employee and conducts activities in the United States and Serbia. In recent developments, Welsis has transitioned into the cryptocurrency and blockchain sector by launching TokenTraders.net, expanding beyond its core teletherapy offerings to include crypto trading capabilities, as noted in its fiscal 2024 quarterly filings. The company reported minimal revenue of $2,000 for fiscal year 2024 ended September 30, alongside a reduced net loss of $24,683 compared to prior periods, while financing operations through convertible notes amid ongoing working capital challenges. No significant acquisitions, partnerships, funding rounds, or major strategic alliances have been publicly disclosed in the last 1-2 years, with focus remaining on development-stage operations and SEC compliance through periodic 10-Q and 10-K filings into 2025.